
Pipeline and Focus - Corbus Pharmaceuticals is expanding its therapeutic focus beyond the endocannabinoid system to include TGF-INTEGRIN biology[4, 6] - Lenabasum, a CB2 agonist, is in Phase 3 development for Dermatomyositis, with topline data expected in Q2 2021, and in Phase 2 for Lupus, with topline data expected in the second half of 2021[7, 14] - The company is developing second-generation CB1 inverse agonists for metabolic and fibrotic diseases[23] - Corbus is also pursuing a CB2 agonist immuno-oncology program targeting solid tumors[7, 41] - CRB-601, an anti-αvβ8 mAb, is being developed for solid tumors, and CRB-602, an anti-αvβ6/8 mAb, is in preclinical development for fibrosis, with Phase 1 trials for CRB-602 estimated to start by the end of 2022[8, 56] Lenabasum in Dermatomyositis - Dermatomyositis affects approximately 80,000 people in North America, EU, and Japan, and has a 30% mortality rate in 5 years[17, 18] - A Phase 2 study of Lenabasum in Dermatomyositis showed improvement in skin activity and biomarkers[18] - The Phase 3 trial in adults with Dermatomyositis has a primary endpoint of ACR & EULAR 2016 Total Improvement Score (TIS) at Week 28, with 176 participants[19] CB1 Inverse Agonists for Metabolic Diseases - Approximately 50% of the US population is obese, and obesity is estimated to rise to 85% by the end of the decade, leading to significant medical costs of ~$480 billion annually[24] - CB1 activation contributes to "Diabesity" by increasing appetite, fat production, insulin resistance, inflammation, and fibrosis, while decreasing insulin secretion and fat oxidation[26] - In a DIO model, the CB1 inverse agonist CRB-556 induced dose-dependent weight loss in obese mice and improved glucose tolerance and insulin sensitivity[34, 35] Financial Status - As of March 31, 2021, Corbus Pharmaceuticals had a cash balance of $125 million, with 125 million common shares outstanding (1401 million fully diluted)[58] - The company is funded through Q1 2024[6]